Orchestra BioMed Holdings, Inc. (OBIO) Stock Chart - Revenue & Earnings | Quarter Chart

📊 Income Statement

Revenue by Product

Revenue by Geography

Revenue, Gross Profit, Operating and Net Income

RevenueGross ProfitOperating IncomeNet Income
0375K750K1M2M2M2M3M3MQ3 2024Q4 2024Q1 2025Q2 2025Q3 2025

Margin (%)

Gross MarginOperating MarginNet Income Margin
0255075100125150175200Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025

Operating Expenses

Research And Development ExpensesSelling General And Administrative Expenses
04M8M11M15M19M22M26M30MQ3 2024Q4 2024Q1 2025Q2 2025Q3 2025

EBITDA

EBITDA
-30M-26M-22M-19M-15M-11M-7M-4M1Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025

EPS

Revenue Variation (%)

Revenue Variation
-90-41856105154202251300Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025

Income Variation (%)

Gross Profit VariationOperating Income Variation
050100150200250300350400Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025

Revenue YoY Variation (%)

Revenue YoY Variation
-208356290118145172200Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025

Income YoY Variation (%)

Gross Profit YoY VariationOperating Income YoY Variation
0255075100125150175200Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025

Price-to-Earning Ratio

P/E Ratio
-4-3-3-2-2-1-001Q3 2024Q4 2024Q1 2025Q2 2025

Income Breakdown

Operating IncomeInterest IncomeTotal Other Income Expenses NetNet Income
0375K750K1M2M2M2M3M3MQ3 2024Q4 2024Q1 2025Q2 2025Q3 2025

Per Share Metrics

Revenue Per ShareNet Income Per ShareOperating Cash Flow Per Share
000001111Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025

Expense Ratios

Research And Ddevelopement To RevenueCapex To RevenueStock Based Compensation To Revenue
0918263544526170Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025
💰 Cash Flow Statement

Operating Cash Flow

Free Cash Flow

Cash At End Of Period
06M12M19M25M31M38M44M50MQ3 2024Q4 2024Q1 2025Q2 2025Q3 2025

Cash Flow to Debt Ratio

Net Cash Provided By Operating ActivitiesNet Cash Used Provided By Financing Activities
011M22M34M45M56M68M79M90MQ3 2024Q4 2024Q1 2025Q2 2025Q3 2025
🏦 Balance Sheet
📈 Key Metrics